Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo
British Journal of Haematology · 2024-12 · 205 (6) · 2338-2348
DOI: 10.1111/bjh.19796 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 08.10.2024. Verfasst von Lin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ataxia Telangiectasia Mutated Proteins, Multiple Myeloma, MAP Kinase Kinase 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH/NCI.
Abstract (Originalsprache)
Mechanisms underlying potentiation of the anti‐myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by MAPK (Mitogen‐activated protein kinases)‐related extracellular kinase 1/2 (MEK1/2) inhibitors were investigated. Co‐administration of the ATR inhibitor (ATRi) BAY1895344 (BAY) and MEK1/2 inhibitors, for example, cobimetinib, synergistically increased cell death in diverse MM cell lines. Mechanistically, BAY and cobimetinib blocked STAT3 Tyr705 and Ser727 phosphorylation, respectively, and dual dephosphorylation triggered marked STAT3 inactivation and downregulation of STAT3 (Signal transducer and activator of transcription 3) downstream targets (c‐Myc and BCL‐X L ). Similar events occurred in highly bortezomib‐resistant (PS‐R) cells, in the presence of patient‐derived conditioned medium, and with alternative ATR (e.g. M1774) and MEK1/2 (trametinib) inhibitors. Notably, constitutively active STAT3 c‐MYC or BCL‐X L ectopic expression significantly protected cells from BAY/cobimetinib. In contrast, transfection of cells with a dominant‐negative form of STAT3 (Y705F) sensitized cells to cobimetinib, as did ATR shRNA knockdown. Conversely, MEK1/2 knockdown markedly increased ATRi sensitivity. The BAY/cobimetinib regimen was also active against primary CD138 + MM cells, but not normal CD34 + cells. Finally, the ATR inhibitor/cobimetinib regimen significantly improved survival in MM xenografts, including bortezomib‐resistant models, with minimal toxicity. Collectively, these findings suggest that combined ATR/MEK1/2 inhibition triggers dual STAT3 Tyr705 and Ser727 dephosphorylation, pronounced downregulation of cytoprotective targets and MM cell death, warranting attention as a novel therapeutic strategy in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Translational Medicine, Asklepios BioPharmaceutical, Inc., Durham, North Carolina, USA.
ORCID-Profile: Liang Zhou, Steven Grant
Förderung
- NCI NIH HHS
- NIH/NCI
Zitieren
APA
Li, L., Hu, X., Nkwocha, J., Kmieciak, M., Meads, M. B., Shain, K. H., Alugubelli, R. R., Silva, A. S., Mann, H., Sudalagunta, P. R., Canevarolo, R. R., Zhou, L., & Grant, S. (2024). Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo. British Journal of Haematology, 205(6), 2338-2348. https://doi.org/10.1111/bjh.19796
Vancouver
Li L, Hu X, Nkwocha J, Kmieciak M, Meads MB, Shain KH, et al. Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo. British Journal of Haematology. 2024;205(6):2338-2348. doi:10.1111/bjh.19796
BibTeX
@article{Li2024,
author = {Li, Lin and Hu, Xiaoyan and Nkwocha, Jewel and Kmieciak, Maciej and Meads, Mark B and Shain, Kenneth H and Alugubelli, Raghunandan R and Silva, Ariosto S and Mann, Hashim and Sudalagunta, Praneeth R and Canevarolo, Rafael R and Zhou, Liang and Grant, Steven},
title = {Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo},
journal = {British Journal of Haematology},
year = {2024},
volume = {205},
number = {6},
pages = {2338--2348},
doi = {10.1111/bjh.19796}
}
EUVIMED